BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Special Report

All Special Reports
Post-AAIC 2017 Alzheimer's Disease US KOL Interview

Retail Price: $599.00

*BioMedTracker Subscriber Price: $399.00 - click here to log in
August 15, 2017
We interviewed a US-based neurologist who specializes in Alzheimer’s disease (AD) treatment to gauge his views on drugs in clinical development for AD, including anti-beta amyloid monoclonal antibodies (mAbs) from Biogen and Roche, beta secretase (BACE) inhibitors from AstraZeneca, Johnson & Johnson and Merck, selective 5-HT6 receptor antagonists from Axovant and Suven and a receptor for advanced glycation end products (RAGE) antagonist from vTv Therapeutics. The specific drugs discussed include aducanumab (BIIB), AVP-786, AZD3293 (AZN), azeliragon (VTVT), crenezumab (RHHBF), gantenerumab (RHHBF), intepirdine (AXON), JNJ-54861911 (JNJ), SUVN-502 and verubecestat (MRK).

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Alzheimer's Disease (AD)